EP Patent

EP1664304A1 — Method for neutralizing effects of secreted pla2 iia

Assigned to Pentracor GmbH · Expires 2006-06-07 · 20y expired

What this patent protects

A compound comprising at least a structural entity which binds secretory phospholipase A2 IIA (sPLA2 IIA) or parts of it and more preferably human sPLA2 IIA and which a.) blocks at least one or more sPLA2 IIA function on cell surfaces or in a solution, preferably blood or other b…

USPTO Abstract

A compound comprising at least a structural entity which binds secretory phospholipase A2 IIA (sPLA2 IIA) or parts of it and more preferably human sPLA2 IIA and which a.) blocks at least one or more sPLA2 IIA function on cell surfaces or in a solution, preferably blood or other body fluids or from tissues, most preferably in vivo, b.) and/or depletes sPLA2 IIA from a solution, preferably blood or other body fluids or from tissues, most preferably in vivo.

Drugs covered by this patent

Patent Metadata

Patent number
EP1664304A1
Jurisdiction
EP
Classification
—
Expires
2006-06-07
Drug substance claim
No
Drug product claim
No
Assignee
Pentracor GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.